[Broncho-Vax and IRS 19 in the treatment of recurrent respiratory tract inflammation in children].
A group of 80 children with relapsing infections of the respiratory pathways (a minimum of three during the previous period) were investigated during the first year of the investigation (1987-88) with regard to the number and duration of the disease, absence from school, antibiotic consumption and use of bronchodilatating agents. In the subsequent year 1988-1989 the children were divided into a group treated with Broncho-Vaxom, a group treated with IRS 19 and a control group. Before the onset of administration and then every two months functional examinations of the lungs were made in the children. At the beginning of treatment and after its termination some immunological and laboratory values were examined. The effect of treatment was evaluated also subjectively by the parents and physician. Both preparations had a favourable effect on prevention of relapses of respiratory infections. This effects was more favourable after Broncho-Vaxom, in particular in prevention of inflammations of the lower respiratory pathways. IRS 19 eliminates relapses of infections of the upper respiratory pathways sooner.
Bánovcin
P
P
Detská klinika MFN, Martin.
Minarik
M
M
Rosslerová
V
V
Miklerová
M
M
Cáp
J
J
Pullmann
R
R
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D001419:Bacteria; D002457:Cell Extracts; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000628:therapy*; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D002457:Cell Extracts; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates; C079233:IRS 19
Broncho-Vaxom a IRS 19 v liecbe recidivujúcich zápalov dýchacich ciest u deti.